Salarius Pharmaceuticals Says FDA Placed Cancer Treatment Trial on Partial Hold; Shares Fall

MT Newswires Live07-12

Salarius Pharmaceuticals (SLRX) said Thursday the US Food and Drug Administration has placed a trial evaluating seclidemstat in combination with azacitidine in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia on partial clinical hold.

This comes after a patient in the University of Texas MD Anderson Cancer Center's sponsored clinical trial experienced "a serious and unexpected" grade-4 adverse event, according to a filing with the US Securities and Exchange Commission.

Under the hold, no new patients may be enrolled, though already enrolled subjects may continue treatment and all study procedures if they are benefiting, Salarius said.

The company's shares were down about 22% in recent trading.

Price: 2.12, Change: -0.59, Percent Change: -21.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2450398818?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-12 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2450398818","market":"hk","top_or_hot":-1,"title":"Salarius Pharmaceuticals Says FDA Placed Cancer Treatment Trial on Partial Hold; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> Salarius Pharmaceuticals (SLRX) said Thursday the US Food and Drug Administration has placed a trial evaluating seclidemstat in combination with azacitidine in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia on partial clinical hold.</p><p>This comes after a patient in the University of Texas MD Anderson Cancer Center's sponsored clinical trial experienced \"a serious and unexpected\" grade-4 adverse event, according to a filing with the US Securities and Exchange Commission.</p><p>Under the hold, no new patients may be enrolled, though already enrolled subjects may continue treatment and all study procedures if they are benefiting, Salarius said.</p><p>The company's shares were down about 22% in recent trading.</p><p>Price: 2.12, Change: -0.59, Percent Change: -21.77</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Salarius Pharmaceuticals Says FDA Placed Cancer Treatment Trial on Partial Hold; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSalarius Pharmaceuticals Says FDA Placed Cancer Treatment Trial on Partial Hold; Shares Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-12 00:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Salarius Pharmaceuticals (SLRX) said Thursday the US Food and Drug Administration has placed a trial evaluating seclidemstat in combination with azacitidine in adult patients with myelodysplastic ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2450398818","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2450398818","pubTimestamp":1720714083,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Salarius Pharmaceuticals  said Thursday the US Food and Drug Administration has placed a trial evaluating seclidemstat in combination with azacitidine in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia on partial clinical hold.This comes after a patient in the University of Texas MD Anderson Cancer Center's sponsored clinical trial experienced \"a serious and unexpected\" grade-4 adverse event, according to a filing with the US Securities and Exchange Commission.Under the hold, no new patients may be enrolled, though already enrolled subjects may continue treatment and all study procedures if they are benefiting, Salarius said.The company's shares were down about 22% in recent trading.Price: 2.12, Change: -0.59, Percent Change: -21.77","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLRX":"Salarius Pharmaceuticals Inc"},"translate_title":"Salarius Pharmaceuticals表示FDA部分搁置癌症治疗试验；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLRX":0.9},"content_text":"Salarius Pharmaceuticals (SLRX) said Thursday the US Food and Drug Administration has placed a trial evaluating seclidemstat in combination with azacitidine in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia on partial clinical hold.This comes after a patient in the University of Texas MD Anderson Cancer Center's sponsored clinical trial experienced \"a serious and unexpected\" grade-4 adverse event, according to a filing with the US Securities and Exchange Commission.Under the hold, no new patients may be enrolled, though already enrolled subjects may continue treatment and all study procedures if they are benefiting, Salarius said.The company's shares were down about 22% in recent trading.Price: 2.12, Change: -0.59, Percent Change: -21.77","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450398818"}